Testing the wrong hypothesis: the failure to recognize the limitations of troponin assays∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Jaffe, Allan S
EDITORIAL COMMENT
Testing the Wrong Hypothesis:
The Failure to Recognize the
Limitations of Troponin Assays*
Allan S. Jaffe, MD, FACC
Rochester, Minnesota
The study by Khan et al. (1) in this issue of the Journal seeks
to determine whether elevated levels of cardiac troponin I
(cTnI) have prognostic significance in “asymptomatic pa-
tients with chronic renal failure” being treated with chronic
hemodialysis. Unfortunately, because of the limitations of
the assay for troponin and the cut values chosen, the study
fails to evaluate this question and serves rather as an example
of an increasing common problem (i.e., attempting to use
troponin assays to make distinctions that are beyond the
analytic capabilities of the assay). Studies with these sorts of
problems, which are proliferating, have the potential to
confuse clinicians about how to use troponin measurements.
See page 991
The question that the study was designed to answer is an
important one. It is now clear as indicated by the investi-
gators that frequent elevations of troponin occur in patients
with renal failure. Although most of the previous studies
have suggested that these elevations have adverse prognostic
significance in this population, most studies have included a
heterogeneous group of patients, including many with
coronary artery disease (CAD). Because CAD is the most
common cause of morbidity and mortality in patients with
renal failure (2), many of the elevations, as in patients with
ischemic heart disease but without renal failure, likely will
have prognostic significance (3). However, it is not at all
clear that all elevations are related to CAD in this group of
patients. There have been reports that elevations in troponin
may be related to the presence of left ventricular hypertro-
phy (LVH) in association with markers of abnormal coro-
nary vasomotion (4), and marked changes in ventricular
volume and thus afterload (i.e., wall stress), which occur
frequently in patients with renal failure, have been suggested
to be the cause of troponin elevations in patients with
congestive heart failure (5).
Furthermore, there are substantial perturbations in pro-
tein synthesis associated with the abnormal metabolic milieu
of renal failure (6). Thus, there likely are elevations in
troponin that may not be due to coronary heart disease, and
there is legitimate question about whether these elevations
also impart an adverse prognosis. From first principles it is
unlikely these abnormalities impart a positive prognosis;
however, the extent to which they may be transient and be
responsive to therapy, and the magnitude of their effect and
the time course during which an effect may be manifest, are
all unclear.
What can be said with greater reassurance is that from the
data available, the troponin being detected comes from the
heart. In the subset of patients with renal failure included in
the study by Ooi et al. (7) (20 of the 78 patients), elevations
of troponin were almost always associated with evidence of
cardiac injury. In addition, multiple studies have attempted
to find evidence of troponin expression in organs other than
the heart in patients with renal failure, and all have thus far
confirmed the fact that neither cTnI nor T values are
elevated for this reason (8–11). From this perspective, the
question Khan et al. (1) want to answer is an important issue
related to whether elevations of cTnI not likely due to CAD
but likely due to other more subtle myocardial injurious
processes can result in an adverse prognosis over time.
The investigators attempt to exclude all patients with
possible ischemic heart disease by eliminating all of those
with any history suggestive of it or with chest discomfort or
electrocardiographic findings suggestive of ischemia. It may
be that they also excluded many but clearly not all of the
patients with volume overload or LVH as well. This
concern could have been obviated by providing more infor-
mation about the patients who were enrolled and at least
some information about the group from which they were
chosen.
The investigators then measured one cTnI value in the
patients and separated the group into those with putative
elevations and those without. It is unclear whether the
clinicians caring for the patients were or were not aware of
the cTnI values or whether any actions were taken in these
patients by those clinicians. Indeed, we know very little at all
about the management of these patients over time.
These patients were then followed for a two-year period.
The primary end point of the study was death or hospital
admission. Why the investigators elected not to use myo-
cardial infarction as an end point is unclear. Indeed, eleva-
tions of troponin substantially over the baseline value with a
pattern characteristic of acute cardiac injury could easily
have been used to confirm the diagnosis. One wonders, was
there a difference in this diagnosis? Similarly, it is unclear
whether the frequency of a percutaneous coronary interven-
tion, which can be done as an outpatient, was similar
between the groups. It would have been helpful for the
investigators to have reassured us in the Results section
about these issues.
Nonetheless, even addressing these issues would not have
saved the study; this is because of the problems related to
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the cut points they chose to use and the analytical charac-
teristics of the assay they employed. It should be appreciated
that the assay chosen was a first-generation assay, with all of
the difficulties of first-generation assays. This is clear from
the literature (12). Unfortunately, at times investigators
wish to lower the cut points for detection using these
first-generation assays when second- and third-generation
assays that are more sensitive become available. At times
that is done without recognizing the analytical problems
that exist. It is the lack of appreciation of the analytical
problems of the assay and cut points used in this study that
casts substantial doubt on the credibility of the results
reported. The analytical problems associated with the approach
used include the following:
1. As with all assays, there is substantial analytical vari-
ability at the lower limit of detection. Being cognizant
of this fact is why so many manufacturers suggested
higher values for diagnosis despite the fact that it was
clear that lower values would likely be of significance.
For this assay, the within-run assay variability was
reported as ,20% for a value of 0.046 ng/ml (12).
Thus, it was likely greater at 0.03 ng/ml, and the
variability between runs is invariably much greater than
the within-run value. Hence, it is likely that the
variability of the assay used for this study was in the
range of 30% to 50%. Taking 50% as an example, which
would not be unexpected given issues such as lot-to-lot
variability, a value of 0.03 ng/ml could be as low as
0.015 ng/ml or as high as 0.045 ng/ml. Accordingly,
the mean values between the group called elevated and
the one called normal probably overlap very substan-
tially and are no doubt similar statistically. From the
standard deviations provided, it appears that there were
very few values that were substantially different from
each other once this high degree of variability was taken
into account. Unfortunately, the raw values are not
provided, but it would not take too many misclassifi-
cations to undercut the validity of the study given the
modest number of patients involved. This problem
could have been diminished to some extent had all
samples been done in duplicate. Even if lower values for
variability are used, the principle is, nonetheless, the
same although the magnitude of the effect might be
lesser.
2. All assays can have problems related to heterophilic
anti-mouse antibodies. There has been some suggestion
that the Beckman assay may be more prone than others.
If the frequency is as suggested for the average assay to
be 1% or 2%, one of two of the elevations, if analytically
real, could have been due to this problem (13).
3. This assay and several other first-generation assays have
been known to have elevations attributable to fibrin
interference. Indeed, all elevations with this assay for
study purposes need to be confirmed after recentrifu-
gation to reduce the importance of this problem (M.
Panteghini, personal communication, 2001). The infor-
mation from Beckman in the package insert emphasizes
this problem and how to reduce its impact.
4. The assay in question is presently being removed from
the market not solely to replace it with a second-
generation assay but because it is now clear that the
epitopes for the antibodies used for detection in this
assay are cleaved from the carboxy terminal both in
myocardium and in blood. Thus, if increases depend on
accumulation over time, they could be missed compared
to other assays due the degradation of the epitopes
needed for detection (14). This could be still more of an
important consideration if cTnI is additionally cleared
by dialysis. Although the investigators quote studies
suggesting that cTnI is not cleared during dialysis,
others suggest it is (15). It may be that the details of
dialysis (dialysis pore size, flow rate and adjunctive
therapy) and the specific assay used may be key factors
in explaining such discrepancies.
5. It is known that there is substantial variability with this
assay if samples are not measured immediately, owing
to the degradation of the epitopes involved with detec-
tion and the fibrin problems mentioned above. Several
examples of this have been presented (M. Panteghini,
personal communication, 2001). The investigators (1)
do not mention whether the assays were done imme-
diately after samples were obtained and spun. If not,
this would introduce still another source of error.
If one considers these issues conjointly, it appears very
likely that the groups were not separated adequately for the
purposes of risk stratification. It is likely that some patients
with elevations were missed due to the high degree of
variability and cleavage of the epitopes of interest; also,
some elevations were spurious. In a study of this size, the
misclassification of even small numbers of patients could
badly skew the results. This lack of ability to separate the
groups raises substantial questions about whether the study
really addressed the question it posed.
Unfortunately, given these considerations, it appears that
the investigators failed to answer the question they posed
about cTnI elevations in asymptomatic patients with renal
failure. However, they have confirmed what clinicians see
and struggle with every day—that is, the assays they believe
they are supposed to rely on do not work in the way that the
experts suggest they should. This is a major problem that
many of us are very concerned about. It has been a
consistent problem in the cardiologic literature where very
few investigators tend to pay attention to these issues.
Until and unless cardiologists and laboratory researchers
join together to promulgate clear standards, these problems
will persist. That is why many of us have championed the
need for consistent standards for cut points and for impre-
cision. The European Society of Cardiology/American Col-
lege of Cardiology (ESC/ACC) (16,17) and the Interna-
tional Federation of Clinical Chemistry and Laboratory
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Medicine (IFCC) (18) have recommended that the cut
points used for decision making be associated with no more
than 10% imprecision. Manufacturers are beginning to
understand this and to develop the techniques to meet this
challenge. Dr. Fred Apple and I, with the support of the
chairs of the ESC/ACC conference on the redefinition of
myocardial infarction, have written to the Food and Drug
Administration (FDA) under their good guidance program,
suggesting that the FDA request and publish the informa-
tion needed to make these decisions for all the troponin
assays they evaluate. In addition, assiduous quality control is
necessary in all aspects of the laboratory efforts in this area
to detect false positives and to consult on the pros and cons
of various assays. It is essential that cardiologists realize that
all assays cannot be used at highly sensitive levels and give
satisfactory answers.
This report (1) is not the last to test the assay involved
and find it wanting. We need to make sure that we
distinguish between studies that do that from those that test
the principle in which we are interested. The issue of
whether troponin elevations are of importance in patients
with renal failure on dialysis who have no evidence of
ischemic heart disease is still one worthy of continuing
research, but only with assays and cut points that allow that
principle to be tested.
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